MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting

by NASDAQ Market News December 9, 2019

NASDAQ Market News
Click here to email author

ContraFect Corporation Announces Proposed Public Offering of Common Stock and Concurrent Private Placement of Common Stock to Pfizer Inc.

Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting

Ads